JB Pharma reports 35 percent increase in PAT at Rs 142 crore in Q1

Published On 2023-08-10 09:00 GMT   |   Update On 2023-08-10 09:00 GMT

New Delhi: JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 35 per cent increase in profit after tax at Rs 142 crore in the first quarter ended June 30, 2023. The company had posted a Profit After Tax (PAT) of Rs 105 crore in the same quarter last fiscal, JB Chemicals & Pharmaceuticals (JB Pharma) said in a statement.Revenue in the quarter under review stood at Rs 896 crore...

Login or Register to read the full article

New Delhi: JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 35 per cent increase in profit after tax at Rs 142 crore in the first quarter ended June 30, 2023. The company had posted a Profit After Tax (PAT) of Rs 105 crore in the same quarter last fiscal, JB Chemicals & Pharmaceuticals (JB Pharma) said in a statement.

Revenue in the quarter under review stood at Rs 896 crore as against Rs 785 crore in the year-ago period, a growth of 14 per cent, it added.

Domestic formulations business stood at Rs 489 crore, a growth of 17 per cent.
Revenue from international business crossed the Rs 400 crore mark for the first time in a quarter, the company said.
"Our domestic business continued its growth trajectory through strong momentum in our chronic portfolio and acquired assets. Our big brands, especially in the chronic segment, continue to outpace the market and have reached new milestones," JB Pharma CEO and Whole Time Director Nikhil Chopra said.
The CDMO (Contract Development and Manufacturing Organisation) business scaled further during the quarter and the healthy momentum continues for this segment too, he added.

Established in 1976, J.B. Pharma, is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News